GLP-1 Drug Usage in America: Trends & Statistics

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The prescription landscape for GLP-1 receptor agonist medications has shifted dramatically over the past three years, with usage rates climbing across multiple patient demographics in the U.S. Recent industry data suggests that approximately 9-15 million Americans have filled at least one GLP-1 prescription, reflecting a fundamental change in how weight loss and metabolic disease are being treated in clinical practice. This surge reflects both improved clinical evidence and growing accessibility through compounded formulations.

How Many Americans Currently Use GLP-1 Medications

Current market analysis indicates that between 9 and 15 million Americans have filled a GLP-1 prescription at some point, making these medications among the most widely prescribed pharmaceutical agents in recent history. The rapid adoption began accelerating in 2022 and has continued climbing steadily through 2024, driven largely by increased insurance coverage, celebrity endorsements, and word-of-mouth success stories from individuals achieving significant weight reduction. Compounded GLP-1 options have further expanded access by eliminating insurance gatekeeping and reducing financial barriers to entry.

Demographic breakdown shows that patients aged 40-65 represent the largest segment of GLP-1 users, though prescription rates are rising notably in younger adults seeking preventive metabolic support. Women constitute approximately 60-65% of the user base, reflecting both higher obesity prevalence in female populations and greater treatment-seeking behavior among women. Type 2 diabetes patients represent roughly 30-40% of total GLP-1 prescriptions, while the remainder are patients pursuing weight loss and cardiovascular risk reduction without diabetes diagnosis.

Growth Trends in GLP-1 Prescription Rates Across the Nation

Prescription growth rates for GLP-1 medications have exceeded 100% year-over-year in multiple calendar periods, outpacing nearly every other medication class tracked by pharmacy benefit managers and compounding pharmacies. Urban and suburban markets have led adoption initially, though rural prescription rates are now accelerating as telehealth-based prescribing platforms reduce geographic barriers. State-level data reveals highest penetration in the Northeast and West Coast, with Southern and Midwest markets showing steeper growth curves as awareness spreads.

Supply chain capacity has become a significant factor limiting growth, with multiple manufacturers and compounding pharmacies struggling to meet demand throughout 2023 and into 2024. This supply constraint has inadvertently created a favorable environment for licensed 503A compounding pharmacies, which offer alternative formulations and personalized dosing protocols that match individual patient metabolism and genetic predisposition. PlexusDx serves all 50 states with compounded semaglutide injections starting at $149 per month, removing geographic and insurance limitations that previously restricted access.

Why GLP-1 Drug Usage Has Increased So Rapidly

Three primary drivers explain the explosive growth in GLP-1 medication adoption over the past 24-36 months. First, landmark clinical trials published between 2021-2023 demonstrated sustained weight loss of 15-22% over 68 weeks in patients taking semaglutide or tirzepatide, substantially outperforming previous pharmaceutical options and behavioral interventions alone. Second, cardiovascular safety data showed that GLP-1 therapy reduced major adverse cardiac events in both diabetic and non-diabetic populations, expanding the therapeutic rationale beyond weight loss into preventive cardiology.

Third, media attention and influencer endorsements dramatically increased public awareness of GLP-1 effectiveness, creating patient demand that pressured healthcare systems to expand access. Insurance coverage expanded accordingly, though formulary restrictions and prior authorization requirements still limit immediate access for many patients. Compounded GLP-1 options bypass these insurance barriers entirely, allowing patients to start therapy within days rather than weeks or months, which has contributed substantially to direct-to-consumer adoption rates.

Understanding Individual Response and Genetic Factors in GLP-1 Treatment

Not all patients respond identically to GLP-1 therapy, and emerging evidence suggests that genetic variation in GLP-1 receptor sensitivity, appetite regulation pathways, and metabolic capacity significantly influences treatment outcomes. The Precision Peptide Genetic Test offered by PlexusDx analyzes 14 distinct peptide and metabolic pathways across 150+ genetic insights, including key variants like GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 that predict individual therapy responsiveness. Patients carrying certain genetic variants may achieve superior results on lower doses of semaglutide, while others might benefit from tirzepatide or dual-compound approaches.

This precision-medicine framework transforms GLP-1 treatment from a one-size-fits-all prescription into a personalized protocol matched to each patient's biochemical profile. PlexusDx adds the Precision Peptide Genetic Test for $99 after the first month of treatment, enabling patients and clinicians to optimize medication selection, dosing strategy, and combination therapy based on measurable genetic predispositions rather than trial-and-error escalation. This approach often reduces side effects, accelerates weight loss timelines, and improves long-term treatment adherence by matching therapy to individual physiologic capacity.

Compounded vs. Brand-Name GLP-1 Options in Today's Market

The distinction between brand-name GLP-1 medications and licensed 503A compounded formulations has become increasingly important as patients navigate cost, access, and availability constraints. Brand-name semaglutide (Ozempic, Wegovy) carries retail prices ranging from $900-$1,500 per month without insurance, while brand-name tirzepatide (Mounjaro, Zepbound) costs $1,000-$1,600 monthly, creating prohibitive barriers for many patients despite clinical eligibility. Licensed 503A compounding pharmacies can manufacture chemically identical semaglutide and tirzepatide at substantially lower cost by sourcing bulk active pharmaceutical ingredients and eliminating manufacturer marketing expenses.

PlexusDx provides compounded semaglutide injections from licensed 503A compounding pharmacies starting at $149 per month flat—no price increases as dose escalates—making treatment accessible nationwide without insurance requirements or membership fees. Patients can also access oral semaglutide at $249 monthly, compounded tirzepatide injections starting at $249 monthly, or the GLP-Squared dual-compound formula blending both agents at $249 monthly for injections. All formulations remain HSA and FSA eligible, and no prior authorization or insurance approval delays access to therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of the U.S. population is currently using GLP-1 medications?

Approximately 3-4% of the total U.S. population has filled a GLP-1 prescription, representing roughly 9-15 million individuals across diabetes, weight loss, and cardiovascular indication categories. Penetration varies significantly by age group and geography, with highest rates in adults aged 40-65 and in urban markets along the Northeast and We...

Does GLP-1 therapy produce better weight loss results than diet and exercise alone?

Clinical trials demonstrate that GLP-1 medications produce 15-22% weight reduction over 68 weeks compared to 2-3% reduction with behavioral intervention alone, representing a 7-10 fold improvement in weight loss efficacy. This superior performance, combined with cardiovascular risk reduction documented in major trials, explains the dramatic shif...

How much does GLP-1 treatment cost through PlexusDx, and do I need insurance?

PlexusDx provides compounded semaglutide injections starting at $149 per month flat, with no your dose may need to go up - your price won't increases. No insurance is required, and all formulations are HSA and FSA eligible, making treatment accessible within days of consultation regardless of insurance status or prior authorization delays.

Are compounded GLP-1 medications as safe and effective as brand-name versions?

Compounded GLP-1 medications from licensed 503A compounding pharmacies contain chemically identical active pharmaceutical ingredients as brand-name formulations, delivering equivalent clinical efficacy and safety profiles. PlexusDx sources exclusively from licensed 503A facilities, never 503B, ensuring pharmaceutical-grade quality, sterility, an...

Can genetic testing help predict how well I'll respond to GLP-1 therapy?

Yes—PlexusDx offers the Precision Peptide Genetic Test for $99 after your first month of treatment, analyzing 14 peptide pathways and 150+ genetic insights including GLP1R and GIPR variants that influence individual medication response. This personalized genetic profile guides optimal compound selection and dosing strategy, often reducing side e...

Understanding the Growing Use of GLP-1 Drugs in the U.S.: How Many People Are On GLP-1 Drugs?